Biomarker-based risk assessment model in acute pulmonary embolism

Area of Science:

• Cardiology
• Pulmonary Medicine
• Biomarker Research

Background:

• Acute pulmonary embolism (APE) poses a significant mortality risk.
• Accurate risk stratification is crucial for managing APE patients.
• Current decision-making levels for APE biomarkers are undefined.

Purpose of the Study:

• To develop and validate a biomarker-based risk stratification strategy for normotensive APE patients.
• To define decision-making levels for cardiac troponin T (cTnT) and NT-proBNP in APE risk assessment.
• To evaluate the prognostic value of cTnT and NT-proBNP in predicting mortality in APE.

Main Methods:

• Prospective study of 100 consecutive normotensive APE patients.
• Serum NT-proBNP and cardiac troponin T (cTnT) levels measured on admission.
• Echocardiography performed to assess cardiac function.
• Analysis of all-cause and APE-specific 40-day mortality.
• Univariable and multivariable analyses to identify independent predictors of mortality.

Main Results:

• 40-day all-cause mortality was 15%; APE mortality was 8%.
• cTnT > 0.07 microg/L and NT-proBNP > 7600 ng/L were significant predictors of mortality in univariable analysis.
• Multivariable analysis identified cTnT > 0.07 microg/L as the strongest independent predictor.
• Patients with NT-proBNP < 600 ng/L had an uncomplicated outcome (0% mortality).
• High-risk group (NT-proBNP ≥ 600 ng/L and cTnT ≥ 0.07 microg/L) had 33% APE mortality.
• Echocardiographic data did not improve risk stratification.

Conclusions:

• Simultaneous measurement of cTnT and NT-proBNP provides precise APE prognosis.
• Normotensive APE patients with cTnT ≥ 0.07 microg/L and NT-proBNP ≥ 600 ng/L are at high risk.
• NT-proBNP < 600 ng/L indicates an excellent prognosis, identifying patients without mortality risk.
• This biomarker panel can guide clinical decision-making in APE management.